Table 5.
Number of quality assessment criteria addressed by individual studies
| Journal articles | |||||||||
| Batty AJ, et al | Giannouchos TV, et al | Hansson-Hedblom A, et al | Hollier-Hann G, et al | Lipton RB, et al | Mahon R, et al | Ruggeri, et al. | Sussman M, et al | Vekov, et al | |
| CHEERS 2022 (n = 28) | |||||||||
| Yes | 25 | 23 | 23 | 23 | 22 | 25 | 23 | 25 | 12 |
| No | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 10 |
| Partial | 1 | 3 | 3 | 2 | 4 | 1 | 3 | 1 | 6 |
| Unclear | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PHILIPS CRITERIA (n = 57) | |||||||||
| Yes | 51 | 50 | 50 | 49 | 51 | 51 | 50 | 51 | 20 |
| No | 3 | 4 | 4 | 6 | 4 | 3 | 3 | 3 | 16 |
| Partial | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 3 | 9 |
| Unclear | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 10 |
| Not applicable | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 |
| Other reports | |||||||||
| CADTH (Botox) | CADTH (Erenumab) | ICER | NICE (Erenumab) | NICE (Fremanezumab) | NICE (Galcenzenumab) | Warwick Evidence (Botox) | |||
| CHEERS 2022 (n = 27) | |||||||||
| Yes | 27 | 26 | 25 | 27 | 27 | 27 | 24 | ||
| No | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Partial | 0 | 1 | 2 | 0 | 0 | 0 | 3 | ||
| Unclear | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| PHILIPS CRITERIA (n = 57) | |||||||||
| Yes | 50 | 49 | 52 | 53 | 54 | 55 | 55 | ||
| No | 3 | 2 | 1 | 2 | 1 | 0 | 0 | ||
| Partial | 4 | 6 | 4 | 1 | 1 | 1 | 2 | ||
| Unclear | 0 | 0 | 0 | 1 | 1 | 1 | 0 | ||
| Not applicable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||